» Articles » PMID: 28880909

In-vivo Biological Activity and Glycosylation Analysis of a Biosimilar Recombinant Human Follicle-stimulating Hormone Product (Bemfola) Compared with Its Reference Medicinal Product (GONAL-f)

Overview
Journal PLoS One
Date 2017 Sep 8
PMID 28880909
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Recombinant human follicle-stimulating hormone (r-hFSH) is widely used in fertility treatment. Although biosimilar versions of r-hFSH (follitropin alfa) are currently on the market, given their structural complexity and manufacturing process, it is important to thoroughly evaluate them in comparison with the reference product. This evaluation should focus on how they differ (e.g., active component molecular characteristics, impurities and potency), as this could be associated with clinical outcome. This study compared the site-specific glycosylation profile and batch-to-batch variability of the in-vivo bioactivity of Bemfola, a biosimilar follitropin alfa, with its reference medicinal product GONAL-f. The focus of this analysis was the site-specific glycosylation at asparagine (Asn) 52 of the α-subunit of FSH, owing to the pivotal role of Asn52 glycosylation in FSH receptor (FSHR) activation/signalling. Overall, Bemfola had bulkier glycan structures and greater sialylation than GONAL-f. The nominal specific activity for both Bemfola and GONAL-f is 13,636 IU/mg. Taking into account both the determined potency and the nominal amount the average specific activity of Bemfola was 14,522 IU/mg (105.6% of the nominal value), which was greater than the average specific activity observed for GONAL-f (13,159 IU/mg; 97.3% of the nominal value; p = 0.0048), although this was within the range stated in the product label. A higher batch-to-batch variability was also observed for Bemfola versus GONAL-f (coefficient of variation: 8.3% vs 5.8%). A different glycan profile was observed at Asn52 in Bemfola compared with GONAL-f (a lower proportion of bi-antennary structures [~53% vs ~77%], and a higher proportion of tri-antennary [~41% vs ~23%] and tetra-antennary structures [~5% vs <1%]). These differences in the Asn52 glycan profile might potentially lead to differences in FSHR activation. This, together with the greater bioactivity and higher batch-to-batch variability of Bemfola, could partly explain the reported differences in clinical outcomes. The clinical relevance of the differences observed between GONAL-f and Bemfola should be further investigated.

Citing Articles

Biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART: a systematic review and meta-analysis.

Kiose K, Storr A, Kolibianakis E, Mol B, Venetis C Hum Reprod. 2024; 40(2):343-359.

PMID: 39719046 PMC: 11788201. DOI: 10.1093/humrep/deae274.


Differential effects of follicle-stimulating hormone glycoforms on the transcriptome profile of cultured rat granulosa cells as disclosed by RNA-seq.

Zarinan T, Espinal-Enriquez J, Anda-Jauregui G, Lira-Albarran S, Hernandez-Montes G, Gutierrez-Sagal R PLoS One. 2024; 19(6):e0293688.

PMID: 38843139 PMC: 11156319. DOI: 10.1371/journal.pone.0293688.


Differential effects of follicle-stimulating hormone glycoforms on the transcriptome profile of cultured rat granulosa cells as disclosed by RNA-seq.

Zarinan T, Espinal-Enriquez J, Anda-Jauregui G, Lira-Albarran S, Hernandez-Montes G, Gutierrez-Sagal R bioRxiv. 2023; .

PMID: 37905087 PMC: 10614937. DOI: 10.1101/2023.10.18.562995.


Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study.

Patel N, Patel N, Patel M, Bhadarka H, Vyas K J Hum Reprod Sci. 2023; 16(2):148-155.

PMID: 37547084 PMC: 10404022. DOI: 10.4103/jhrs.jhrs_37_23.


Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy?.

Lispi M, Humaidan P, Bousfield G, DHooghe T, Ulloa-Aguirre A Int J Mol Sci. 2023; 24(10).

PMID: 37240364 PMC: 10218858. DOI: 10.3390/ijms24109020.


References
1.
Bousfield G, Butnev V, Bidart J, Dalpathado D, Irungu J, Desaire H . Chromatofocusing fails to separate hFSH isoforms on the basis of glycan structure. Biochemistry. 2008; 47(6):1708-20. DOI: 10.1021/bi701764w. View

2.
Orvieto R, Seifer D . Biosimilar FSH preparations- are they identical twins or just siblings?. Reprod Biol Endocrinol. 2016; 14(1):32. PMC: 4908720. DOI: 10.1186/s12958-016-0167-8. View

3.
Ulloa-Aguirre A, Timossi C, Damian-Matsumura P, Dias J . Role of glycosylation in function of follicle-stimulating hormone. Endocrine. 2000; 11(3):205-15. DOI: 10.1385/ENDO:11:3:205. View

4.
Ulloa-Aguirre A, Timossi C, Mendez J . Is there any physiological role for gonadotrophin oligosaccharide heterogeneity in humans? I. Gondatrophins are synthesized and released in multiple molecular forms. A matter of fact. Hum Reprod. 2001; 16(4):599-604. DOI: 10.1093/humrep/16.4.599. View

5.
Wide L, Eriksson K . Dynamic changes in glycosylation and glycan composition of serum FSH and LH during natural ovarian stimulation. Ups J Med Sci. 2013; 118(3):153-64. PMC: 3713380. DOI: 10.3109/03009734.2013.782081. View